-Advertisement-
Autoimmune PAP
Inhaled molgramostim shows long-term benefits for aPAP patients in real-world case series
Inhaled molgramostim, a recombinant GM-CSF, shows promising long-term therapeutic benefits for patients with autoimmune pulmonary alveolar proteinosis (aPAP), according to a real-world case series. Currently, the standard treatment for aPAP is whole-lung lavage, however, whole-lung lavage does not address the underlying cause of the disease. As a result, there is...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
Videos
29 Oct, 2024
Swaminathan Perinkulam Sathyanarayanan, MBBS, a second-year fellow in pulmonary and...
Quizzes
-Advertisement-
Contact
© 2025 Med Journal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved